Psoriatic Juvenile Idiopathic Arthritis

Categories: Bone diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Psoriatic Juvenile Idiopathic Arthritis

MalaCards integrated aliases for Psoriatic Juvenile Idiopathic Arthritis:

Name: Psoriatic Juvenile Idiopathic Arthritis 53 72
Psoriasis-Related Juvenile Idiopathic Arthritis 53 59 17
Juvenile Psoriatic Arthritis 53 59 72
Psoriasis-Related Jia 53 59
Juvenile Arthritis 72


Orphanet epidemiological data:

psoriasis-related juvenile idiopathic arthritis
Age of onset: Childhood; Age of death: normal life expectancy;


External Ids:

ICD10 via Orphanet 34 L40.5+ M09.0*
UMLS via Orphanet 73 C0409672
Orphanet 59 ORPHA85436
UMLS 72 C3495559 C3714758 C3890176

Summaries for Psoriatic Juvenile Idiopathic Arthritis

NIH Rare Diseases : 53 Psoriatic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis that is characterized by both arthritis and psoriasis. Other signs and symptoms may include dactylitis (inflammation and swelling of an entire finger or toe); nail pitting or splitting; and eye problems. Although the underlying cause of psoriatic juvenile idiopathic arthritis is currently unknown (idiopathic), it is thought to occur due to a combination of genetic and environmental factors. It is very rare for more than one member of a family to have juvenile arthritis; however, research suggests that having a family member with juvenile arthritis or any autoimmune disease may increase the risk of having juvenile arthritis, in general. Treatment usually involves different types of medications to help manage symptoms and/or physical therapy.

MalaCards based summary : Psoriatic Juvenile Idiopathic Arthritis, also known as psoriasis-related juvenile idiopathic arthritis, is related to arthritis and familial mediterranean fever. An important gene associated with Psoriatic Juvenile Idiopathic Arthritis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and skin, and related phenotypes are arthralgia and pruritus

Related Diseases for Psoriatic Juvenile Idiopathic Arthritis

Diseases related to Psoriatic Juvenile Idiopathic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 arthritis 30.0 PSTPIP1 NOD2
2 familial mediterranean fever 27.9 PSTPIP1 NOD2 NLRP3 MEFV
3 juvenile rheumatoid arthritis 11.9
4 pustulosis of palm and sole 10.5
5 psoriasis 10.5
6 psoriatic arthritis 10.2
7 spondyloarthropathy 1 10.2
8 inflammatory spondylopathy 10.2
9 spondylitis 10.2
10 juvenile ankylosing spondylitis 10.1
11 exanthem 10.1
12 arthropathy 10.1
13 uveitis 10.0
14 rheumatic disease 10.0
15 synovitis 10.0
16 tenosynovitis 10.0
17 hereditary periodic fever syndrome 10.0
18 autoimmune disease 9.9
19 celiac disease 1 9.9
20 osteoid osteoma 9.9
21 branchiootic syndrome 1 9.9
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
23 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
24 hydrops, lactic acidosis, and sideroblastic anemia 9.9
25 autosomal recessive disease 9.9
26 sensorineural hearing loss 9.9
27 renal hypertension 9.9
28 glomerulonephritis 9.9
29 inner ear disease 9.9
30 acute kidney failure 9.9
31 skin disease 9.9
32 anterior uveitis 9.9
33 autoimmune inner ear disease 9.9
34 polyarticular juvenile idiopathic arthritis 9.9
35 cervical adenitis 9.9 NLRP3 MEFV
36 familial cold autoinflammatory syndrome 1 9.9 NLRP3 MEFV
37 erysipeloid 9.8 NLRP3 MEFV
38 periodic fever, familial, autosomal dominant 9.8 NLRP3 MEFV
39 cinca syndrome 9.8 NLRP3 MEFV
40 muckle-wells syndrome 9.8 NLRP3 MEFV
41 wells syndrome 9.7 NLRP3 MEFV
42 aphthous stomatitis 9.7 NLRP3 MEFV
43 amyloidosis 9.4 NLRP3 MEFV
44 lig4 syndrome 9.3 NOD2 NLRP3
45 pyoderma 9.3 PSTPIP1 NOD2 MEFV
46 behcet syndrome 9.2 PSTPIP1 NOD2 MEFV
47 blau syndrome 9.1 NOD2 NLRP3 MEFV
48 pyoderma gangrenosum 8.7 PSTPIP1 NOD2 NLRP3 MEFV

Graphical network of the top 20 diseases related to Psoriatic Juvenile Idiopathic Arthritis:

Diseases related to Psoriatic Juvenile Idiopathic Arthritis

Symptoms & Phenotypes for Psoriatic Juvenile Idiopathic Arthritis

Human phenotypes related to Psoriatic Juvenile Idiopathic Arthritis:

59 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 59 Frequent (79-30%)
2 pruritus 59 Frequent (79-30%)
3 skin rash 59 Occasional (29-5%)
4 psoriasiform dermatitis 59 Frequent (79-30%)
5 limitation of joint mobility 59 Occasional (29-5%)
6 autoimmunity 59 Frequent (79-30%)
7 reduced visual acuity 59 Occasional (29-5%)
8 uveitis 59 Occasional (29-5%)
9 abnormality of the shoulder 59 Occasional (29-5%)
10 abnormality of the temporomandibular joint 59 Very rare (<4-1%)
11 nail pits 59 Frequent (79-30%)
12 abnormality of the wrist 59 Occasional (29-5%)
13 antinuclear antibody positivity 59 Frequent (79-30%)
14 abnormality of the knee 59 Occasional (29-5%)
15 onycholysis 59 Very rare (<4-1%)
16 anterior uveitis 59 Occasional (29-5%)
17 iritis 59 Very rare (<4-1%)
18 iridocyclitis 59 Very rare (<4-1%)
19 malar rash 59 Occasional (29-5%)
20 polyarticular arthritis 59 Frequent (79-30%)
21 enthesitis 59 Frequent (79-30%)
22 abnormality of tumor necrosis factor secretion 59 Very frequent (99-80%)
23 finger dactylitis 59 Frequent (79-30%)
24 toe dactylitis 59 Frequent (79-30%)
25 oligoarthritis 59 Frequent (79-30%)
26 generalized morning stiffness 59 Occasional (29-5%)
27 psoriasiform lesion 59 Occasional (29-5%)
28 sacroiliac arthritis 59 Very rare (<4-1%)

MGI Mouse Phenotypes related to Psoriatic Juvenile Idiopathic Arthritis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.26 MEFV NLRP3 NOD2 PSTPIP1
2 immune system MP:0005387 8.92 MEFV NLRP3 NOD2 PSTPIP1

Drugs & Therapeutics for Psoriatic Juvenile Idiopathic Arthritis

Drugs for Psoriatic Juvenile Idiopathic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
leucovorin Approved Phase 4 58-05-9 143 6006
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
Etanercept Approved, Investigational Phase 4 185243-69-0
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
8 Immunologic Factors Phase 4
9 Folic Acid Antagonists Phase 4
10 Folate Phase 4
11 Vitamin B9 Phase 4
12 Nucleic Acid Synthesis Inhibitors Phase 4
13 Vitamin B Complex Phase 4
14 Immunosuppressive Agents Phase 4
15 Dermatologic Agents Phase 4
16 Antimetabolites Phase 4
17 Antirheumatic Agents Phase 4
18 Antimetabolites, Antineoplastic Phase 4
19 Cyclooxygenase Inhibitors Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Vaccines Phase 4
23 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
24 Liver Extracts Phase 4
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
Infliximab Approved Phase 2, Phase 3 170277-31-3
Tofacitinib Approved, Investigational Phase 3 477600-75-2
Certolizumab pegol Approved Phase 3 428863-50-7
29 Anti-Inflammatory Agents Phase 2, Phase 3
30 Gastrointestinal Agents Phase 2, Phase 3
31 Antineoplastic Agents, Immunological Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 3
33 Protein Kinase Inhibitors Phase 3
34 Antibodies Phase 3
35 Antibodies, Monoclonal Phase 3
36 Immunoglobulins Phase 3
37 Mitogens Phase 3
Prednisolone phosphate Approved, Vet_approved Phase 1 302-25-0
Methylprednisolone Approved, Vet_approved Phase 1 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 1 2921-57-5
Prednisolone Approved, Vet_approved Phase 1 50-24-8 5755
Prednisolone hemisuccinate Experimental Phase 1 2920-86-7
43 Hormones Phase 1
44 Hormone Antagonists Phase 1
45 Neuroprotective Agents Phase 1
46 glucocorticoids Phase 1
47 Methylprednisolone Acetate Phase 1
48 Antiemetics Phase 1
49 Antineoplastic Agents, Hormonal Phase 1
50 Protective Agents Phase 1

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
2 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
3 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
4 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
5 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
6 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Active, not recruiting NCT01734382 Phase 4 Tocilizumab
7 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
8 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
10 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
11 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
12 An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis Recruiting NCT03769168 Phase 3 AIN457
13 A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773978 Phase 3 Baricitinib;Placebo
14 A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773965 Phase 3 Baricitinib
16 A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis Active, not recruiting NCT03031782 Phase 3 AIN457
17 A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA) Active, not recruiting NCT01550003 Phase 3 Certolizumab Pegol (CZP)
18 A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy Terminated NCT01230827 Phase 3 CNTO 148 (Golimumab);Placebo;Methotrexate
19 Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years Terminated NCT00174291 Phase 3 Somatropin
20 The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis Completed NCT00213187 Phase 2
21 An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA) Completed NCT01513902 Phase 1 CP-690,550;CP-690,550;CP-690,550
22 Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome Recruiting NCT02780583 Phase 1 kineret;placebo
23 Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive. Unknown status NCT02343770
24 Research Registry for Juvenile Arthritis Unknown status NCT00090571
25 Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study Completed NCT00195377 Etanercept
26 Humira® for Subcutaneous Injection Special Investigation ( All-case Survey ) in Patients With Juvenile Idiopathic Arthritis Study Completed NCT01412021
27 ARTEMIS Synovial Markers in Arthritis Childhood Completed NCT02505828
28 LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System Completed NCT00487565
29 Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis Completed NCT02030613
30 Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis Completed NCT00004420 gamma-Linolenic acid
31 Jointstrong Intervention for Juvenile Arthritis Completed NCT01166750
32 C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France Completed NCT02886689 TNF-alpha antagonist and other biotherapy
33 High Resolution Infrared Thermographic Imaging as a Diagnostic Aid for Acute Undifferentiated Limp in Children. Completed NCT03312348
34 Multicenter, Diagnostic and Prospective Study to Differentiate Child Septic and Inflammatory Arthritis by Comparative Analysis Recruiting NCT03827759
35 iCanCope With Pain: Usability and Feasibility Testing of a Smartphone Application to Manage Pain in Youth With Arthritis Recruiting NCT02764346
36 Fertility Study of Women With Chronic Inflammatory Rheumatism Recruiting NCT03452735
37 The Development and Validation of Quantitative Imaging Biomarkers as a Measure of Disease Activity in Juvenile Idiopathic Arthritis Recruiting NCT02684695
38 Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation (PETITE) Active, not recruiting NCT03383263
39 A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE Active, not recruiting NCT00783510 Methotrexate
40 Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis Active, not recruiting NCT02218892
41 Start Time Optimization of Biologics in Polyarticular JIA Active, not recruiting NCT02593006
42 Chronic Non-inflammatory Pains in Rheumatopediatrics Not yet recruiting NCT03740347
43 Massage Therapy for Children With Juvenile Idiopathic Arthritis Experiencing Pain: a Pilot Randomized Controlled Trial Terminated NCT02218580
44 Reducing Problematic Substance Use in Youth With Chronic Medical Conditions Withdrawn NCT01709201
45 The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis Withdrawn NCT00836394
46 Pilot Study: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis Withdrawn NCT01114243

Search NIH Clinical Center for Psoriatic Juvenile Idiopathic Arthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Diclofenac Potassium
Diclofenac Sodium
Methotrexate Sodium
Naproxen sodium
Tolmetin Sodium

Genetic Tests for Psoriatic Juvenile Idiopathic Arthritis

Anatomical Context for Psoriatic Juvenile Idiopathic Arthritis

MalaCards organs/tissues related to Psoriatic Juvenile Idiopathic Arthritis:

Eye, Liver, Skin, Testes, Bone

Publications for Psoriatic Juvenile Idiopathic Arthritis

Articles related to Psoriatic Juvenile Idiopathic Arthritis:

# Title Authors PMID Year
Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. 38
25774101 2015
Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. 38
24191219 2013
Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. 38
21709556 2011
Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. 38
18576390 2008

Variations for Psoriatic Juvenile Idiopathic Arthritis

Expression for Psoriatic Juvenile Idiopathic Arthritis

Search GEO for disease gene expression data for Psoriatic Juvenile Idiopathic Arthritis.

Pathways for Psoriatic Juvenile Idiopathic Arthritis

GO Terms for Psoriatic Juvenile Idiopathic Arthritis

Cellular components related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeleton GO:0005856 9.13 PSTPIP1 NOD2 MEFV
2 lamellipodium GO:0030027 8.62 PSTPIP1 MEFV

Biological processes related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.61 PSTPIP1 NLRP3 MEFV
2 immune system process GO:0002376 9.56 PSTPIP1 NOD2 NLRP3 MEFV
3 cellular response to lipopolysaccharide GO:0071222 9.54 NOD2 NLRP3
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.52 NOD2 NLRP3
5 defense response GO:0006952 9.51 NOD2 NLRP3
6 negative regulation of inflammatory response GO:0050728 9.49 NLRP3 MEFV
7 protein complex oligomerization GO:0051259 9.48 NOD2 NLRP3
8 regulation of inflammatory response GO:0050727 9.46 NOD2 NLRP3
9 innate immune response GO:0045087 9.46 PSTPIP1 NOD2 NLRP3 MEFV
10 positive regulation of interleukin-1 beta secretion GO:0050718 9.4 NOD2 NLRP3
11 positive regulation of type 2 immune response GO:0002830 9.37 NOD2 NLRP3
12 cellular response to peptidoglycan GO:0071224 9.32 NOD2 NLRP3
13 detection of biotic stimulus GO:0009595 8.96 NOD2 NLRP3
14 cytokine secretion involved in immune response GO:0002374 8.62 NOD2 NLRP3

Molecular functions related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.13 PSTPIP1 NLRP3 MEFV
2 peptidoglycan binding GO:0042834 8.62 NOD2 NLRP3

Sources for Psoriatic Juvenile Idiopathic Arthritis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....